<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helwick, Caroline</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hida, Toyoaki</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Sequential Therapy with Gefitinib for Advanced Non-Small Cell Lung Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">In previous studies, gefitinib combined with chemotherapy has provided no survival gain compared with chemotherapy alone for patients with advanced non-small cell lung cancer (NSCLC). However, a phase 3 trial has shown that sequential therapy with gefitinib may offer clinical benefit after platinum-based doublet chemotherapy in this setting. The West Japan Thoracic Oncology Group trial [WJTOG 0203; NCT00144066] involved patients who were randomly assigned to 3–6 cycles of chemotherapy alone (298 patients) or to 3 cycles of chemotherapy followed by daily gefitinib until disease progression (300 patients).</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>